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Essentials
• ADAMTS13 requires a substrate-induced conforma-
tional change to attain full activity in vitro.
• The efficacy of wild type ADAMTS13 in models of
thrombosis/stroke may be enhanced by pre-activation.
• A pre-activated ADAMTS13 variant exhibits enhanced
proteolysis of platelet agglutinates.
• This ADAMTS13 variant is protective in a murine
model of stroke at a lower dose than WT ADAMTS13.
Summary. Background: ADAMTS-13 circulates in a
closed conformation, only achieving full proteolytic activ-
ity against von Willebrand factor (VWF) following a sub-
strate-induced conformational change. A gain-of-function
(GoF) ADAMTS-13 variant (R568K/F592Y/R660K/
Y661F/Y665F) is conformationally preactivated. Objec-
tives: To establish how the hyperactivity of GoF
ADAMTS-13 is manifested in experimental models mim-
icking the occlusive arterial thrombi present in acute
ischemic stroke. Methods: The ability of GoF ADAMTS-
13 to dissolve VWF–platelet agglutinates was examined
with an assay of ristocetin-induced platelet agglutination
and in parallel-flow models of arterial thrombosis. A
murine model of focal ischemia was used to assess the
thrombolytic potential of GoF ADAMTS-13. Results:
Wild-type (WT) ADAMTS-13 required conformational
activation to attain full activity against VWF-mediated
platelet capture under flow. In this assay, GoF
ADAMTS-13 had an EC50 value more than five-fold
lower than that of WT ADAMTS-13 (0.73  0.21 nM
and 3.81  0.97 nM, respectively). The proteolytic activity
of GoF ADAMTS-13 against preformed platelet aggluti-
nates under flow was enhanced more than four-fold as
compared with WT ADAMTS-13 (EC50 values of
2.5  1.1 nM and 10.2  5.6 nM, respectively). In a mur-
ine stroke model, GoF ADAMTS-13 restored cerebral
blood flow at a lower dose than WT ADAMTS-13, and
partially retained the ability to recanalize vessels when
administration was delayed by 1 h. Conclusions: The lim-
ited proteolytic activity of WT ADAMTS-13 in in vitro
models of arterial thrombosis suggests an in vivo require-
ment for conformational activation. The enhanced activ-
ity of the GoF ADAMTS-13 variant translates to a more
pronounced protective effect in experimental stroke.
Keywords: ADAMTS-13 protein; conformational
activation; hemostasis; stroke; von Willebrand factor.
Introduction
Evidence has been accumulating that implicates von
Willebrand factor (VWF) as an important factor in the
pathophysiology of acute ischemic stroke (AIS) [1]. VWF
is an adhesive plasma glycoprotein (GP) that is secreted
and circulates as large globular multimers [2–5]. In this
globular conformation, VWF is quiescent and unable to
capture platelets. At sites of vascular damage, VWF is
tethered to the vessel wall through its constitutively
exposed collagen-binding site in the A3 domain [6,7].
Under the shear force of flowing blood, the unfolding of
its A2 domain [8–10] induces conformational changes at a
macromolecular scale [11], and local conformational
changes in the A1 domain expose the previously cryptic
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platelet GP)1b-binding site [11]. The ability of VWF to
capture platelets and to initiate the formation of the pla-
telet plug is dependent on its multimeric size, and is regu-
lated by the plasma metalloprotease ADAMTS-13
[12,13].
Experimental studies in VWF/ and ADAMTS13/
mice have confirmed the importance of the
VWF–ADAMTS-13 axis for the extent of ischemic injury
[14–17]. Recombinant ADAMTS-13 (rADAMTS-13) has
systemic antithrombotic activity in ADAMTS13/ mice
[16]. Furthermore, rADAMTS-13 has been shown to have
protective effects in murine stroke models without the
risk of intracranial hemorrhage associated with recombi-
nant tissue-type plasminogen activator (rt-PA) [18]. The
VWF content of patient clots has been suggested to be a
determining factor in rt-PA resistance [19]. Moreover, a
recent study identified VWF-rich patient clots and
demonstrated the efficacy of rADAMTS-13 against
rt-PA-resistant, VWF-rich thrombi in mice [20].
Recently, our understanding of ADAMTS-13 function
has developed with the identification of a substrate-
induced conformational activation mechanism [21–24]. In
this model, ADAMTS-13 circulates in a quiescent confor-
mation, maintained by an autoinhibitory interaction
between its N-terminal spacer domain and its C-terminal
CUB domains [21]. This autoinhibition is relieved upon
binding of ADAMTS-13 to the D4-CK domains of glob-
ular VWF, exposing the crucial spacer domain exosite in
readiness for VWF A2 domain unfolding. Exposure of
ADAMTS-13 to the VWF D4-CK domains results in an
approximately three-fold enhancement of its activity. A
gain-of-function (GoF) ADAMTS-13 spacer domain vari-
ant (R568K/F592Y/R660K/Y661F/Y665F), which was
first described by Jian et al. [25], is preactivated because
of the mutagenic disruption of the autoinhibitory spacer–
CUB domain interaction. This results in enhanced activ-
ity, even in the absence of VWF D4-CK. This variant
also has the potential for broadened substrate specificity,
and there are reports of in vitro proteolytic activity
against both fibrinogen and plasminogen [26,27].
We hypothesized that the previously identified, dose-
dependent activity of wild-type (WT) ADAMTS-13 in
murine models of stroke may be further improved by
conformational preactivation. We tested this hypothesis
by using an in vitro parallel-flow model of platelet clump-
ing under arterial shear conditions, before comparing the
efficacy of WT ADAMTS-13 with that of GoF
ADAMTS-13 in in vitro models of thrombosis and in a
murine model of AIS.
Materials and methods
Protein expression and purification
Recombinant human ADAMTS-13 with a C-terminal
Myc/His6 tag in pCDNA3.1 [28] was used to generate
GoF ADAMTS-13 (R568K/F592Y/R660K/Y661F/
Y665F) by sequential site-directed mutagenesis. For
in vitro experiments ADAMTS-13 was expressed in
HEK293S stable cell lines and quantified, in conditioned
medium, with an in-house ELISAs as described previ-
ously [28,29]. For half-life determination, ADAMTS-13
was expressed in either HEK293S or CHO-K1 stable cell
lines, and purified by fast protein liquid chromatography
(FPLC) with zinc-coupled HiTrap chelating columns
(GE Healthcare, Chicago, IL, USA). CHO-expressed
ADAMTS-13, for use in the murine stroke model, was
passed over a hydroxyapatite column to remove contami-
nating proteins, and the purified ADAMTS-13 was quan-
tified with an in-house ELISA and dialyzed into 150 mM
NaCl, 20 mM histidine, 2% sucrose, and 0.05% Tween-80
(pH 7.4). The dimeric VWF D4-CK domain fragment
(VWF residues 1874–2813) in the vector pcDNA 3.1/His
was transiently expressed in HEK293S, purified by FPLC,
and quantified by ELISA as previously described [30].
Parallel-flow assays
For parallel-flow assays, performed in the absence of coag-
ulation, Vena8 Fluoro+ biochips (Cellix, Dublin, Ireland)
were coated with 200 lg mL1 collagen type III (Southern
Biotech, Birmingham, AL, USA) and blocked with 1%
bovine serum albumin (BSA) and 1 mg mL1 glucose in
HEPES buffer. Whole donor blood was collected on
PPACK (Sigma, Gillingham, UK) and enoxaparin (low
molecular weight heparin from Sanofi-Aventis, Guildford,
UK), and treated with 100 nM prostaglandin E1 (PGE1)
(Sigma) and 75 mU mL1 apyrase (Sigma), to prevent pla-
telet activation. Platelets were labeled with 10 lM DiOC6
(Sigma), and perfused over the collagen surface at a con-
stant shear rate of 1500 s1 (at which rate platelet capture is
VWF-dependent) for 3.5 min. Adhesion of labeled platelets
was visualized by fluorescence imaging at 250-ms intervals
with a 9 20 objective, and analyzed with SLIDEBOOK software
to determine platelet coverage (%) at 180 s. To determine the
effect of ADAMTS-13 on platelet capture, the assay was also
performed in the presence of WT or GoF ADAMTS-13 at a
range of concentrations, and EC50 values were determined from
dose–response curves with GRAPHPAD 7. To assess the effect of
ADAMTS-13 on preformed platelet aggregates, the assay was
altered to allow 5 min of perfusion in the absence of
rADAMTS-13, before a further 5 min of perfusion in the pres-
ence of rADAMTS-13 (WT or GoF). For parallel-flow assays,
performed in the presence of coagulation, Vena8 Fluoro+ bio-
chips were coated with 200 lg mL1 collagen type III and
100 pM tissue factor (Sigma) before being blocked with coagu-
lation buffer (1% BSA, 75 mM CaCl2 and 37.5 mM MgCl2 in
HEPES buffer). Whole human blood was collected in 129 mM
trisodium citrate (1 : 10 dilution), and platelets were labeled
with 10 lM DiOC6. Citrated blood was diluted 9 : 1 with coag-
ulation buffer immediately before perfusion over the collagen/
tissue factor-coated surface at 1500 s1 for 3 min. This was
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repeated three times to provide uninterrupted flow of coagulat-
ing blood for a sufficient time to allow the formation of stable
pseudothrombi. This was followed by a further 5 min of perfu-
sion with blood, collection on PPACK and enoxaparin, and
supplementation with DiOC6-labeled platelets and rADAMTS-
13 (WT or GoF).
Platelet agglutination assay
Donor blood was collected in 85 mM sodium citrate,
111 mM glucose, and 71 mM citric acid (pH 4.5). Washed
platelets were prepared and treated with 100 nM PGE1
(Sigma) and 75 mU mL1 apyrase (Sigma), to prevent
platelet activation. Platelets were incubated with
10 lg mL1 VWF (purified from plasma), and agglutina-
tion was initiated by the addition of 0.6 mg mL1
ristocetin (Helena Bioscience, Gateshead, UK). Light
transmission was recorded with a Chrono-Log dual chan-
nel aggregometer (Kordia BV, Leiden, the Netherlands).
After 5 min, once stable agglutination was observed,
ADAMTS-13 (WT or GoF) was administered and light
transmission was recorded for a further 30 min.
FRETS-VWF73 assay
The FRETS-VWF73 assays of ADAMTS-13 activity were
performed as described previously [21,24]. Purified VWF
D4-CK (20–60 nM) was added before a 45-min preincuba-
tion at 37°C. Results were normalized to WT ADAMTS-
13 activity.
Determination of ADAMTS-13 half-life in murine plasma
All animal work was performed in compliance with ani-
mal ethics guidelines at Imperial College London accord-
ing to the UK Home Office’s Animals (Scientific
Procedures) Act 1986, in accordance with the local ethi-
cal law and local ethical committees (KU Leuven, Leu-
ven, Belgium; act no. 87–848) and following guidelines
for the care and use of laboratory animals. Age-matched
and sex-matched C57BL/6 littermates, aged 6–8 weeks,
were anesthetized with ketamine (75 mg kg1) and
medetomidine (1 mg kg1). The injection of ADAMTS-
13 was performed through the retro-orbital plexus, and
blood samples were taken via the same route into
129 mM citrate. Plasma concentrations of ADAMTS-13
were determined with an in-house ELISA as previously
described [28,29]. To derive t1/2 values, data were plot-
ted, by use of a one-phase decay equation, in GRAPH-
PAD 7.
Murine focal ischemia stroke model
FeCl3-induced occlusion of the middle cerebral artery
(MCA) was performed with surgical techniques described
previously [20]. Regional cerebral blood flow (rCBF) in
the MCA territory was determined by laser Doppler flow
monitoring, and infarct size was determined 24 h after
occlusion of the MCA by staining brain sections with 2%
2,3,5-triphenyl-tetrazolium chloride, both as described
previously [20].
Results
rADAMTS-13 requires conformational activation for full
function in in vitro models of platelet clumping
In a previous study of GoF ADAMTS-13 [26], the vari-
ant showed increased efficacy in reducing the VWF-
mediated capture of washed plaletets under parallel flow,
as compared with WT ADAMTS-13. This was attributed
to the variant’s preactivated state and the requirement of
WT ADAMTS-13 for conformational activation. To
investigate the dependence of WT ADAMTS-13 activity
on conformational activation by VWF, and the hyperac-
tivity of the GoF variant, in a physiological setting, we
performed parallel-flow assays with whole human blood
under arterial shear rates. In these assays, in which plate-
let capture is VWF-dependent, the addition of 2.5 nM
WT rADAMTS13 elicited only a slight reduction in plate-
let capture over time (Fig. 1A). When WT ADAMTS-13
was preincubated with 100 nM VWF D4-CK prior to
being added to the assay, there was a significant decrease
(P < 0.005) in the platelet coverage recorded at the end of
the assay (Fig. 1A,B). The extent of the decrease in plate-
let capture in the presence of conformationally activated
WT ADAMTS-13 was similar to that observed in the
presence of GoF ADAMTS-13 (Fig. 1A,B). The activity
of GoF ADAMTS-13 was not further enhanced by the
addition of VWF D4-CK. Dose–response curves were
generated by titrating both WT and GoF ADAMTS-13
into the platelet capture assay and determining the plate-
let coverage after 270 s of blood perfusion (Fig. 1C,D).
These plots were used to determine EC50 values of
3.81  0.97 nM and 0.73  0.21 nM for WT and GoF
ADAMTS-13, respectively.
Preactivated GoF ADAMTS-13 shows enhanced ability to
dissolve VWF–platelet agglutinates/aggregates
Having established that WT ADAMTS-13 requires con-
formational activation for full activity against VWF in a
physiological setting, we hypothesized that this may limit
its ability to dissolve preformed VWF–platelet aggluti-
nates, and that the GoF variant would not be limited in
this manner. This was first investigated in an agglutina-
tion assay with washed platelets. In this assay, ristocetin-
induced VWF unfolding triggers the formation of platelet
agglutinates before the addition of ADAMTS-13. In the
presence of WT ADAMTS-13, the agglutination of plate-
lets continued to increase steadily over the course of
30 min (Fig. 2A,B). In samples treated with GoF
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ADAMTS-13, there was initial partial dissolution of pla-
telet agglutinates (Fig. 2A) and a 30–50% decrease in the
final agglutination as compared with that in the WT
ADAMTS-13-treated samples (Fig. 2B; P < 0.001).
The ability of ADAMTS-13 to dissolve preformed
VWF–platelet aggregates in whole blood was examined
under arterial shear rates, under conditions in which plate-
let capture was VWF-dependent (Fig. 1A,B). After 5 min
of perfusion of whole blood over a collagen-coated surface,
approximately 60–70% of the surface was covered by
labeled platelets. During a second 5-min period of perfu-
sion with whole blood containing endogenous ADAMTS-
13, this remained stable (Fig. 2C,D). When endogenous
ADAMTS-13 was inhibited (AD13 NEG) by the addition
of an inhibitory mAb (3H9), the platelet coverage contin-
ued to increase steadily throughout the second period of
perfusion (Fig. 2C,D). With titration of WT and GoF
ADAMTS-13 into this assay during the second perfusion
period (Fig. 2C,D), EC50 values were determined for the
dissolution of VWF–platelet aggregates, i.e. 10.2  5.6 nM
and 2.5  1.1 nM, respectively (Fig. 2E).
GoF ADAMTS-13 reduces the size of in vitro preformed
pseudothrombi
To examine the ability of WT and GoF ADAMTS-13 to
dissolve preformed pseudothrombi, the parallel-flow assay





































































































Fig. 1. Recombinant wild-type (WT) ADAMTS-13 is only partially active in whole blood under flow. (A) Whole human blood, collected on
PPACK and clexane, was perfused over a collagen-coated surface at arterial shear rate, and the von Willebrand factor (VWF)-mediated cap-
ture of labeled platelets (%) was recorded over time (Control). This was repeated with the addition of either 2.5 nM ADAMTS-13 (WT or
gain-of-function [GoF]) with or without preincubation with 100 nM VWF D4-CK (+). As a VWF-negative control, blood was preincubated
with an inhibitory mAb (6B4) to block the VWF–glycoprotein 1b interaction (VWF NEG). As an ADAMTS-13-negative control, blood was
preincubated with an inhibitory anti-ADAMTS-13 mAb (3H9) to inhibit endogenous ADAMTS-13 (AD13 NEG). The curves are representa-
tive of three independent experiments. (B) For each sample, platelet coverage (%) was determined at the end (180 s) of the experiment, and
pairwise t-tests were performed between WT and GoF ADAMTS-13 and their corresponding VWF D4-CK-activated samples (***P < 0.005).
Results are mean  standard deviation (SD), n = 3–6. (C, D) WT ADAMTS-13 and the GoF variant were then tested at a range of concentra-
tions in the same assay. For comparison, VWF-negative controls are included in (C). All results are given as mean  SD, n = 3. CON, control;
NS, not significant.
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of platelet aggregates in the presence of induced coagula-
tion and fibrin deposition. Unlike the previous parallel-
flow assays performed in the presence of anticoagulants,
this assay generated large, stable platelet aggregates
(Fig. 3), which have been shown previously to contain
fibrin(ogen) [26]. When channels containing these pseu-
dothrombi were further perfused with whole blood con-
taining endogenous ADAMTS-13, there was some
remodeling of the pseudothrombi (Fig. 3A), most of
which were enlarged, resulting in a steady increase in the
DiOC6 fluorescence attributable to the ongoing incorpo-
ration of platelets into the thrombus (Fig. 3D). In the
presence of added WT ADAMTS-13 (at the normal
plasma concentration), there was still enlargement of the
pseudothrombi (Fig. 3B); however, the extent of the fluo-
rescence increase was somewhat reduced (Fig. 3D). When
treated with GoF ADAMTS-13, the pseudothrombi
underwent extensive remodeling (Fig. 3C), and, at the
end of the second perfusion period, the size of the pseu-
dothrombi (as measured by platelet fluorescence) was
significantly reduced (P < 0.005) as compared with the
fluorescence at t = 0 (Fig. 3D).
Characterization of ADAMTS-13 for in vivo administration
For in vivo studies, rADAMTS-13 (WT and GoF) was
expressed in CHO-K1 stable cell lines, which have been
shown in previous studies to generate ADAMTS-13 with
a long half-life in murine experiments. This has been
attributed to an altered pattern of glycosylation as com-
pared with ADAMTS-13 expressed in HEK293 cell lines
[14]. This material required extensive purification with a
combination of techniques, designed to remove protein
contaminants without affecting ADAMTS-13 activity.
The results presented so far herein, and in all of our pre-
vious studies of GoF ADAMTS-13 [21,24,26], have been
generated by the use of material expressed in HEK293S
cell lines. Characterization of the purified, CHO-expressed
ADAMTS-13 was therefore required. There was no sig-
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Fig. 2. Gain-of-function (GoF) ADAMTS-13 is more effective in the dissolution of preformed von Willebrand factor (VWF)–platelet aggluti-
nates and in the lysis of preformed VWF–platelet aggregates under flow. (A) Agglutination of washed platelets (100 000 lL1) was initiated by
the addition of 10 lg mL1 plasma VWF and 0.6 mg mL1 ristocetin. Once maximal agglutination was achieved (5 min), 50 nM ADAMTS-13
(wild-type [WT] or GoF variant) was injected, and light transmission was followed for a further 25 min. Curves are representative of n = 8.
(B) The effect of ADAMTS-13 on platelet agglutinates was quantified at 30 min. Results are mean  standard deviation (SD), n = 8
(****P < 0.001). (C, D) Whole human blood, collected on PPACK and clexane, containing labeled platelets was perfused over a collagen sur-
face at arterial shear for 5 min to form VWF–platelet aggregates. At the end of this period (t = 0 min), the channel was perfused for a further
5 min with blood containing either WT or GoF ADAMTS-13 (0–50 nM) or blood treated with an inhibitory anti-ADAMTS-13 (3H9) mAb
(AD13 NEG). Fluorescence was recorded throughout the second period of perfusion, and was normalized to the fluorescence at t = 0 min. (E)
The normalized fluorescence at t = 5 min was determined for each ADAMTS-13-treated sample. All results are mean  SD, n = 3.
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VWF73) of WT ADAMTS-13 preparations expressed in
HEK or CHO cell lines and no significant difference in
the activity of CHO-expressed WT ADAMTS-13 before
and after purification (Fig. 4A). The activity of CHO-
expressed GoF ADAMTS-13 was enhanced approxi-
mately three-fold as compared with that of WT
ADAMTS-13 (Fig. 4A). This was similar to the activity
of the HEK-expressed GoF ADAMTS-13, here and in
previous studies, and this was not altered upon purifica-
tion. As expected, the activity of the CHO-expressed WT
ADAMTS-13, but not that of the GoF variant, was dose-
dependently enhanced by the addition of the VWF D4-
CK domain fragment (Fig. 4A). A comparison of the
half-lives of WT and GoF ADAMTS-13 confirmed the
rapid clearance of HEK-expressed ADAMTS-13 from
murine plasma (Fig. 4B,C), with t1/2 values of
10.6  0.45 min and 9.3  0.58 min, respectively. Half-
lives could not be determined for CHO-expressed
ADAMTS-13, as the plasma concentrations (in mice
injected with either WT or GoF ADAMTS-13) decreased
by only 5–10% over the course of the experiment.
GoF ADAMTS-13 restores cerebral blood flow after
experimental stroke and reduces cerebral ischemia at a
lower dose than WT ADAMTS-13
As GoF ADAMTS-13 shows an increased ability to dis-
solve VWF/platelet-rich aggregates in vitro, we hypothe-
sized that it may exert a more pronounced protective
effect than WT ADAMTS-13 in an experimental model
of stroke. Large, VWF-rich thrombotic occlusions were
generated in the MCAs of C57BL/6 mice. Occlusion was
defined by reduction of rCBF to < 25% of baseline (de-
termined by laser Doppler flowmetry) that remained
stable for 5 min. In vehicle-only controls, rCBF remained
stable for a period of 60 min, and no spontaneous
recanalization, defined as a return of rCBF to > 25% of
baseline, was observed (Fig. 5A). Mice were injected with
WT or GoF ADAMTS-13 at a final concentration of
200, 400 or 800 nM, and body weight was used to esti-
mate the total blood volume. There was no restoration of
blood flow in any of the mice injected (n = 5) with



































Fig. 3. Gain-of-function (GoF) ADAMTS-13 partially dissolves von Willebrand factor (VWF)/platelet-rich pseudothrombi under flow. (A)
Whole human blood, collected on citrate and containing labeled platelets, was recalcified immediately prior to perfusion over a collagen/tissue
factor-coated surface. After 9 min of continuous perfusion, large, VWF/platelet-rich pseudothrombi (shown previously to also contain fibrin
(ogen) [26]) were formed. At the end of this period (t = 0 min) the channel was perfused for a further 4 min with labeled, recalcified blood,
and platelet fluorescence was continuously monitored. (B, C) The assay was repeated with the addition of 5 nM ADAMTS-13 (wild-type [WT]
or GoF) during the second perfusion period. Images are representative of three independent experiments. (D) Fluorescence readings for each
sample were normalized to that at t = 0 min, and are expressed as mean  SD, n = 3. [Color figure can be viewed at wileyonlinelibrary.com]
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restoration of blood flow in only one of the mice injected
(n = 5) with 200 nM GoF ADAMTS-13 (Fig. 5C). The
mean rCBF of the five mice injected with 400 nM WT
ADAMTS-13 did not significantly increase above the
recanalization threshold of 25% (Fig. 5A), with only two
mice showing restored blood flow (Fig. 5C). Injection of
400 nM GoF ADAMTS-13 (n = 5) resulted in a mean
rCBF that was significantly higher than the recanalization
threshold (Fig. 5A), with two mice showing rCBF above
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Fig. 4. Characterization of recombinant ADAMTS-13 expressed in CHO cell lines and purified for in vivo experiments. (A) The proteolytic
activities of ADAMTS-13 expressed in HEK293S and CHO K1 stable cell lines (in conditioned medium) and purified ADAMTS-13 expressed
in CHO K1 cells were determined with the FRETS-VWF73 assay. Pairwise t-tests showed no significant difference in the activity of
ADAMTS-13 expressed in the two different cell lines or between purified ADAMTS-13 and that in conditioned medium. The enhancement of
purified ADAMTS-13 activity by VWF D4-CK was also determined. The activity of each VWF D4-CK-treated sample was compared with the
corresponding ADAMTS-13 activity (**P < 0.01, ****P < 0.001). All results are mean  standard deviation (SD), n = 3. (B, C) Adult wild-
type (WT) C57bl6 mice were injected with purified ADAMTS-13 (WT or gain-of-function [GoF]) expressed in either HEK293S or CHO K1
cell lines. The plasma ADAMTS-13 antigen level in these mice was determined at 5, 20 and 40 min after injection. Results are mean  SD,
n = 3–5. VWF, von Willebrand factor.
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n = 7), both WT and GoF ADAMTS-13 elicited a rapid
and sustained increase in the mean rCBF above the
recanalization threshold (Fig. 5B), similar to that seen in
previous studies of WT ADAMTS-13 [20]. The restora-
tion of blood flow in these mice equated to a significant
decrease in infarct volume 24 h after stroke, as compared
with the vehicle-only group (P < 0.01). This was true for
the groups treated with 400 nM or 800 nM GoF
ADAMTS-13, but only in the 800 nM group for WT
ADAMTS-13 (Fig. 5D).
The ability of GoF ADAMTS-13 to reduce the size of
preformed, stable platelet aggregates in vitro suggested
that its protective effect in experimental stroke may be
sustained even when administration is delayed. Delayed
administration of both WT and GoF ADAMTS-13 at a
single dose of 800 nM was evaluated. Although highly
variable, and therefore not statistically significant, the
injection of GoF ADAMTS-13 at 60 min after occlusion
did result in a small increase in the mean rCBF above the
recanalization threshold (Fig. 5E), with six of the seven
mice in the group showing some level of blood flow
restoration as compared with only two mice in the WT
group (Fig. 5F). Despite these results, there was no
observable improvement in terms of infarct volume 24 h
after stroke (Fig. 5G).
Discussion
Under physiological conditions (arterial flow rate in the
presence of the plasma concentration of VWF) WT
ADAMTS-13 is not fully active
In previous studies of GoF ADAMTS-13, first described
by Jian et al. [25], the hyperactivity of the variant was
similar to that of conformationally activated WT
ADAMTS-13 [21,24]. Therefore, it is described as being
preactivated. In an assay of the VWF-mediated capture
of platelets from plasma-free blood, performed under
flow, the GoF variant showed a similar level of enhanced
activity (approximately three-fold to four-fold decrease in
EC50) as that observed in static assays [26]. This
suggested that, under these conditions, WT ADAMTS-13
was not conformationally activated. We set out to estab-
lish whether or not WT ADAMTS-13 is conformationally
active under conditions that better reflect the physiologi-
cal setting of arterial thrombus formation, to allow us to
establish whether or not preactivated GoF ADAMTS-13
would be a more potent thrombolytic agent in vivo.
In parallel-flow assays, in which platelet capture is
dependent on the unfolding of VWF (present at the nor-
mal plasma concentration) by arterial shear, WT
ADAMTS-13 was clearly less active than the GoF variant
(Fig. 1A,B). However, preincubation of WT ADAMTS-
13 with 100 nM VWF D4-CK (2.5 times the plasma con-
centration of monomeric VWF) results in an activity that
is comparable to that of GoF ADAMTS-13. This
strongly suggests that the physiological activity of WT
ADAMTS-13 is, in part, dependent on the availability
and/or binding affinity of the D4-CK domains within
plasma VWF. The fact that the activity of GoF
ADAMTS-13 in this assay cannot be further enhanced by
VWF D4-CK is indicative of a preactivated state, as seen
in static assays and in previous platelet capture assays
[21,24,26]. This is further supported by the decrease in
the EC50 determined for the GoF variant as compared
with WT ADAMTS-13 (Fig. 1C,D). The fact that the
activity of WT ADAMTS-13 is dependent, at least in
part, on its conformational activation may be an impor-
tant consideration, as the recombinant protein may be
useful as a potential therapy for thrombotic thrombocy-
topenic purpura [31,32] and ischemic stroke [20].
The preactivated state of GoF ADAMTS-13 increases its
ability to dissolve platelet agglutinates/aggregates in vitro
WT ADAMTS-13 requires activation by the D4-CK
domains of VWF to attain full activity against VWF
under flow. In a physiological setting, in which VWF
binds to collagen and platelets as it is incorporated into
the developing platelet plug, reduced access to the activat-
ing D4-CK domains may further limit the efficacy of WT
ADAMTS-13. Therefore, we hypothesized that
Fig. 5. Gain-of-function (GoF) ADAMTS-13 restores cerebral blood flow and reduces infarct size in a murine model of ischemic stroke at a
lower dose than wild-type (WT) ADAMTS-13. (A, B) Adult WT C57bl6 mice underwent FeCl3-mediated middle cerebral artery occlusion
(MCAO), characterized by a reduction in regional cerebral blood flow (rCBF) to below 25% of baseline (determined by laser doppler flowme-
try). At 5 min after stable occlusion, mice were injected with either WT ADAMTS-13 (closed circles), GoF ADAMTS-13 (open circles) or vehi-
cle only (closed squares, n = 12), and rCBF was monitored for a further 60 min. This was performed with an ADAMTS-13 plasma
concentration of either 400 nM (A, n = 5) or 800 nM (B, n = 7). Results are mean  standard deviation (SD). Changes in laser Doppler blood
flow were analyzed and compared by the use of repeated measures ANOVA. (C) The proportion of mice in which ADAMTS-13 treatment
restored rCBF to > 25%, > 50% or <75%, 60 min after injection. (D) At 24 h after MCAO, mice were killed, and cerebral infarct volume was
determined by 2,3,5-triphenyltetrazolium chloride (Sigma) staining. Stained brain sections were photographed, and infarct areas were analyzed
via planimetry with IMAGE J software (http://imagej.nih.gov/ij/) by an experimenter who was blinded to treatment conditions. An unpaired Stu-
dent’s t-test or one-way ANOVA with Dunnett’s multiple comparison test was used for statistical comparison of infarct lesions, when applicable
(**P < 0.05). Results are mean  SD. (E) The ability of WT ADAMTS-13 (800 nM, closed circles) and GoF ADAMTS-13 (800 nM, open cir-
cles) to restore rCBF in the MCAO model was also assessed when administration was delayed by 60 min. Results are mean  SD, n = 7. (F)
The proportion of mice in which delayed ADAMTS-13 treatment restored rCBF to >25%, >50% or <75%, 60 min after injection. (G) No sig-
nificant reduction in infarct volume was observed in mice treated with delayed ADAMTS-13 administration (mean  SD, n = 7) as compared
with the vehicle group (n = 12). VEH, vehicle.
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preactivated GoF ADAMTS-13 may be better able to
proteolyze VWF that is already incorporated into platelet
aggregates, thereby reducing the size of preformed
thrombi.
We first examined this in an assay of ristocetin-induced
platelet agglutination, allowing the formation of VWF–pla-
telet agglutinates before the addition of ADAMTS-13. The
inability of WT ADAMTS-13 to dissolve the preformed
agglutinates was clearly evident (Fig. 2A,B), in contrast to
previous studies in which WT ADAMTS-13 reduced plate-
let agglutination [20]. This may be the result of differences
in ADAMTS-13 concentration and/or activity between the
ADAMTS-13 used here (prepared in-house) and the com-
mercial ADAMTS-13 preparation used previously [20].
Comparatively, GoF ADAMTS-13 showed an ability to
reduce the size of the agglutinates, which was evident from
the 30–50% reduction in agglutination determined by light
transmission measurements (Fig. 2A,B), and from visual
inspection of the cuvette contents upon completion. The
increased efficacy of GoF ADAMTS-13 against preformed
platelet aggregates was also evident when it was examined
under flow, where it showed an EC50 value four times lower
than that of WT ADAMTS-13 (Fig. 2C–E). We also
employed a more physiologically relevant model in which
the complexity of the fibrin-containing pseudothrombi
would be expected to further hinder the conformational
activation, and therefore the efficacy, of WT ADAMTS-13.
Indeed, WT ADAMTS-13, at least at physiological concen-
tration, was unable to reduce the size of the thrombi, and
only partially reduced the ongoing incorporation of plate-
lets as compared with the control (Fig. 3A,B,D). The GoF
variant, on the other hand, not only prevented ongoing pla-
telet recruitment, but actively remodeled and reduced the
size of the pseudothrombi (Fig. 3C,D).
GoF ADAMTS-13 shows enhanced thrombolytic activity and
is protective in a murine model of AIS
Finally, we examined the efficacy of WT and GoF
ADAMTS-13 in an established murine model of AIS. The
formation of occlusive thrombi in this model, achieved
through topical administration of FeCl3 to the MCA, has
been shown previously to be highly dependent on VWF.
Therefore, this is a relevant model of rt-PA-resistant
thrombi, and is useful for demonstrating how targeting
VWF can induce recanalization [20]. With its preactivated
conformation, and enhanced proteolytic activity against
VWF (Fig. 4A), it was hypothesized that GoF ADAMTS-
13 would be more effective at dissolving these VWF-rich
thrombi. This was true, to some extent, as GoF ADAMTS-
13 remained protective at a lower dose than WT
ADAMTS-13, in terms of both rCBF restoration
(Fig. 5A–C) and infarct volume reduction (Fig. 5D). The
fact that GoF ADAMTS-13 was effective at lower doses
than WT ADAMTS-13 most likely reflects the enhanced
activity of the preactivated ADAMTS-13 variant, which
could become useful in the setting of stroke. The enhanced
ability of GoF ADAMTS-13 to reduce the size of estab-
lished pseudothrombi in vitro led us to examine whether or
not it would remain effective at restoring blood flow in the
AIS model when administration was delayed by 1 h.
Again, this was observed to some extent, as a greater pro-
portion of mice treated with GoF ADAMTS-13 showed
partially restored rCBF as compared with those treated
with WT ADAMTS-13 (Fig. 5E,F). However, this was not
reflected in infarct volume measurements (Fig. 5G). Previ-
ous studies showed that WT ADAMTS-13 was able to
reduce infarct size when administration was delayed by 1 h
[20]. Although it is difficult to compare the concentrations
used in this study, a difference in absolute concentration
could explain this difference. The half-lives of the WT
ADAMTS-13 and GoF ADAMTS-13 used in these experi-
ments was not determined; however, there was negligible
reduction in the plasma concentration of either protein
over a similar time period (Fig. 4B,C). Furthermore, the
half-lives of WT and GoF ADAMTS-13 (expressed in
HEK293S cells) in murine plasma were comparable.
In summary, the enhanced activity of preactivated
ADAMTS-13 (as compared with WT ADAMTS-13) in
in vitro assays of platelet capture (Fig. 1B) suggests that,
at plasma ADAMTS-13/VWF concentrations, the activity
of ADAMTS-13 can be further increased. The fact that
GoF ADAMTS-13 does not require conformational acti-
vation appears to result in increased efficacy in a model
of AIS, which may reduce the required dose. Further
studies of the therapeutic potential of GoF ADAMTS-13
in the setting of ischemic stroke, focusing particularly on
thromboinflammatory stroke, are required, as is further
investigation into the possibility of broadened substrate
specificity and the possible impact of this on the variant’s
safety and efficacy in vivo.
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